Interim Report - January to March 2020

Pressmeddelanden   •   Maj 15, 2020 09:30 CEST

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its First Quarter Report for 2020.

Affibody and Inmagene Announce Strategic Partnership to Develop ABY-035 – A Phase 2 Drug Candidate with Best-in-Class Potential for Auto-Immune Diseases

Pressmeddelanden   •   Maj 15, 2020 08:00 CEST

Solna, Sweden & Shanghai, China, May 15, 2020. Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced a strategic partnership to develop and commercialize ABY-035, a bispecific molecule targeting Interleukin-17A (IL-17), for multiple auto-immune diseases.

Affibody Announces Option Exercise by Daewoong

Pressmeddelanden   •   Apr 30, 2020 09:07 CEST

Solna, Sweden, April 30, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced that its partner Daewoong, a South Korea-based pharmaceutical company, has exercised an option under the companies’ ongoing collaboration.

Year End Report 2019

Pressmeddelanden   •   Feb 21, 2020 13:01 CET

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Full Year Report for 2019.

Notice of EGM (Kallelse till extra bolagsstämma)

Nyheter   •   Feb 03, 2020 13:19 CET

Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma måndagen den 17 februari 2020 kl 14.00 i bolagets lokaler, Scheeles väg 2, Solna.

Interim Report – January to September 2019

Pressmeddelanden   •   Nov 15, 2019 08:30 CET

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter of 2019.

Affibody Relocates to the Karolinska Institute Campus in Solna

Pressmeddelanden   •   Sep 23, 2019 08:05 CEST

Solna, Sweden, September 23, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative bi- and multi-specific drug projects, today announced its relocation to the Karolinska Institute Campus in Solna.

Affibody and GE Healthcare to Collaborate on Development of Affibody® PET Imaging Tracers

Pressmeddelanden   •   Sep 20, 2019 08:15 CEST

Solna, Sweden, September 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced a strategic collaboration with GE Healthcare to develop and commercialize Affibody®-based PET imaging tracers, with initial focus on HER2 and PD-L1. Financial terms were not disclosed.

Interim Report – January to June 2019

Pressmeddelanden   •   Aug 23, 2019 08:30 CEST

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the second quarter of 2019.

Affibody Announces Interim Analysis in Phase 2 Psoriasis Trial of ABY-035

Pressmeddelanden   •   Jul 16, 2019 16:00 CEST

Solna, Sweden, July 16, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of the planned 12 week interim analysis in the Company’s Phase 2 proof-of-concept study of its bispecific molecule ABY-035 for moderate-to-severe psoriasis (“AFFIRM-35”).

Bilder & Videor 1 bild

Kontaktpersoner 4 kontaktpersoner

Om Affibody

Developing Next Generation Biopharmaceuticals

Affibody is a clinical stage Swedish biotech company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

Affibody AB is a holding of Patricia Industries. For more information on Affibody, please visit the company’s website at www.affibody.com

Adress

  • Affibody
  • Scheeles väg 2
  • SE-171 65 SOLNA